PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33718411-6 2021 CRP, LDH, and D-dimer serum levels were also lowered in metformin-treated patients compared to non-metformin treated patients (p = 0.0001). Metformin 56-65 C-reactive protein Homo sapiens 0-3 33412927-9 2021 RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Based on available evidence from RCTs in this meta-analysis, metformin decreased CRP level. Metformin 110-119 C-reactive protein Homo sapiens 130-133 33412927-11 2021 CONCLUSION: The present study evidences that therapy with metformin can reduces CRP level significantly in T2D patients compared to other inflammatory markers. Metformin 58-67 C-reactive protein Homo sapiens 80-83 32859615-8 2020 Compared with control, exercise and metformin reduced sTNF-alphaR2: -13.1% (95% CI: -22.9, -1.0) and IL-6: -38.7% (95% CI: -52.3, -18.9); but did not change hs-CRP: -20.5% (95% CI: -44.0, 12.7). Metformin 36-45 C-reactive protein Homo sapiens 160-163 32639009-9 2020 Treatment with metformin or a synthetic AMPK activator may be a potential strategy for vaso-dysfunction and hypertension in patients with high hCRP levels. Metformin 15-24 C-reactive protein Homo sapiens 143-147 32342619-7 2020 The significant improvements found only in the metformin group were body mass index, fasting blood glucose, high-sensitivity C-reactive protein and 10-year risk of coronary heart disease (Framingham heart study) (P = 0.0004, P = 0.049, P = 0.035 and P = 0.029); whereas that only in the placebo group was high density lipoprotein cholesterol. Metformin 47-56 C-reactive protein Homo sapiens 125-143 29168915-5 2018 Interestingly, "high-risk" T2DM patients characterized by severe chemotaxis impairment reveal significantly higher C-reactive protein levels and poor lipid metabolism characteristics as compared to "low-risk" subjects, and their neutrophil chemotaxis responses can be mitigated after in vitro metformin treatment. Metformin 293-302 C-reactive protein Homo sapiens 115-133 31006835-9 2020 CONCLUSIONS: Breast cancer patients receiving metformin as treatment for diabetes showed significant reduction in levels of insulin, fasting glucose, CRP, HOMA, leptin, BMI, and Ki-67. Metformin 46-55 C-reactive protein Homo sapiens 150-153 31326727-0 2019 Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Metformin 32-41 C-reactive protein Homo sapiens 97-115 30427060-8 2019 Finally, KDM individuals on metformin treatment exhibited significantly lower levels of sCD14, sCD163 and CRP compared with those on non-metformin-containing regimens. Metformin 28-37 C-reactive protein Homo sapiens 106-109 30890498-9 2019 Our results showed that metformin treatment decreased MAIBD and relapse frequency in the patients, and significantly lowered the clinical inflammatory indexes including CRP and ESR. Metformin 24-33 C-reactive protein Homo sapiens 169-172 29803716-11 2018 For CRP, a significant small to medium effect was observed with probiotics (-0.43 mg/L), ARBs (-0.2 mg/L), omega-3 (-0.17 mg/L) and metformin (-0.16 mg/L). Metformin 132-141 C-reactive protein Homo sapiens 4-7 31474368-4 2019 We show that microbes integrate cues from metformin and the diet through the phosphotransferase signaling pathway that converges on the transcriptional regulator Crp. Metformin 42-51 C-reactive protein Homo sapiens 162-165 29880175-4 2018 High sensitive C-reactive protein levels (hsCRP) changed with OC, combination and metformin therapies by 102.32%, 3.2% and -7.14%, respectively. Metformin 82-91 C-reactive protein Homo sapiens 15-33 28081696-12 2018 After Metformin therapy, FBS, PPB and HbA1c%, Hs- CRP and fetuin decreased (rho<=0.001) while eGDR and insulin dose in units/kg increased (rho <0.001). Metformin 6-15 C-reactive protein Homo sapiens 50-53 28953677-0 2017 Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: A PRISMA-compliant article. Metformin 11-20 C-reactive protein Homo sapiens 50-68 28953677-1 2017 BACKGROUND: Metformin is effective for the treatment of polycystic ovary syndrome (PCOS), but conflicting results regarding its impact on serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in women with PCOS have been reported. Metformin 12-21 C-reactive protein Homo sapiens 154-172 28953677-1 2017 BACKGROUND: Metformin is effective for the treatment of polycystic ovary syndrome (PCOS), but conflicting results regarding its impact on serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in women with PCOS have been reported. Metformin 12-21 C-reactive protein Homo sapiens 174-177 28953677-2 2017 To provide high-quality evidence about the effect of treatment with metformin on CRP and IL-6 in PCOS, relevant studies that assessed the serum levels of CRP and IL-6 in women with PCOS receiving metformin treatment were reviewed and analyzed. Metformin 68-77 C-reactive protein Homo sapiens 81-84 28953677-7 2017 Data suggest that serum levels of CRP were decreased after metformin treatment in PCOS patients with an SMD (95% CI) of -0.86 [-1.24 to -0.48] and P = .000 (random-effects). Metformin 59-68 C-reactive protein Homo sapiens 34-37 28953677-13 2017 In addition, we noticed that metformin treatment could decrease BMI in the CRP and IL-6 related studies (SMD = -0.45, 95% CI: -0.68 to -0.23; SMD = -0.44, 95% CI: -0.73 to -0.16). Metformin 29-38 C-reactive protein Homo sapiens 75-78 28404960-0 2017 Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis. Metformin 10-19 C-reactive protein Homo sapiens 23-41 28404960-1 2017 The impact of the recommended first-line treatment with metformin on C-reactive protein (CRP) levels in patients with polycystic ovary syndrome (PCOS) is still controversial. Metformin 56-65 C-reactive protein Homo sapiens 69-87 28404960-1 2017 The impact of the recommended first-line treatment with metformin on C-reactive protein (CRP) levels in patients with polycystic ovary syndrome (PCOS) is still controversial. Metformin 56-65 C-reactive protein Homo sapiens 89-92 28404960-2 2017 We conducted a meta-analysis of studies reporting the impact of metformin on serum CRP levels in women with PCOS. Metformin 64-73 C-reactive protein Homo sapiens 83-86 28404960-6 2017 CRP levels significantly decreased after metformin treatment (WMD = -1.23mg/L, 95%CI: -1.65 to -0.81, I2 = 93% and P < 0.001 for heterogeneity). Metformin 41-50 C-reactive protein Homo sapiens 0-3 28404960-8 2017 Interestingly, the degree of decreased CRP levels was not depended on metformin dosage, but more significantly in patients treated beyond 6 months (WMD>=6months = -1.47mg/L vs. WMD<6months = -0.94 mg/L). Metformin 70-79 C-reactive protein Homo sapiens 39-42 28404960-11 2017 Therefore, metformin shows the potential effects on CRP levels in women with PCOS. Metformin 11-20 C-reactive protein Homo sapiens 52-55 28404960-12 2017 However, considering the very low quality of evidence for the analysis, the effect of metformin on CRP levels are still very uncertain, and large-scale randomized-controlled study is needed to ascertain the long-term effects of metformin in PCOS. Metformin 86-95 C-reactive protein Homo sapiens 99-102 26950284-7 2016 The fasting plasma hs-CRP and FGF-21 levels were significantly decreased in the T2DM group after metformin treatment compared with pretreatment (respectively, 2.56 +- 1.75 mg/L vs. 3.28 +- 1.89 mg/L [P < 0.05] and 232.6 pg/mL [range, 154.3-307.8 pg/mL] vs. 313.9 pg/mL [range, 227.7-474.2 pg/mL] [P < 0.01]). Metformin 97-106 C-reactive protein Homo sapiens 22-25 27018756-15 2016 Metformin significantly (P < .05) reduced insulin, BP, CRP, and PAI-1 levels. Metformin 0-9 C-reactive protein Homo sapiens 58-61 25740979-1 2015 BACKGROUND: Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. Metformin 12-21 C-reactive protein Homo sapiens 96-114 25277876-0 2016 Relationship of the Serum CRP Level With the Efficacy of Metformin in the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis. Metformin 57-66 C-reactive protein Homo sapiens 26-29 25277876-2 2016 This meta-analysis was conducted to investigate whether CRP was sensitive in predicting the efficacy of metformin in the treatment of T2DM. Metformin 104-113 C-reactive protein Homo sapiens 56-59 25277876-7 2016 Pooled SMD of those studies revealed that serum levels of CRP and hs-CRP significantly decreased in patients with T2DM after receiving the metformin treatment. Metformin 139-148 C-reactive protein Homo sapiens 58-61 25277876-7 2016 Pooled SMD of those studies revealed that serum levels of CRP and hs-CRP significantly decreased in patients with T2DM after receiving the metformin treatment. Metformin 139-148 C-reactive protein Homo sapiens 69-72 25277876-8 2016 Subgroup analysis by country yielded significant different estimates in the serum levels of CRP between the baseline and after metformin treatment in the China, Israel and India subgroups; but only detected only in the China subgroup considering serum levels of hs-CRP. Metformin 127-136 C-reactive protein Homo sapiens 92-95 25277876-9 2016 Follow-up time-stratified analyses indicated that serum levels of CRP were markedly reduced in the metformin-treated group in all subgroups. Metformin 99-108 C-reactive protein Homo sapiens 66-69 25277876-11 2016 CONCLUSION: Decreased serum levels of CRP and hs-CRP may contribute to a more sensitive prediction in providing a more accurate efficacy reference in the metformin drug in T2DM patients. Metformin 154-163 C-reactive protein Homo sapiens 38-41 25277876-11 2016 CONCLUSION: Decreased serum levels of CRP and hs-CRP may contribute to a more sensitive prediction in providing a more accurate efficacy reference in the metformin drug in T2DM patients. Metformin 154-163 C-reactive protein Homo sapiens 49-52 25607338-3 2015 In this study, the authors aimed to compare the anti-inflammatory properties of pioglitazone and metformin, with respect to their effect on serum concentrations of highly sensitive C-reactive protein (hsCRP), osteoprotegerin (OPG), intercellular adhesion molecule-1 (ICAM-1) and adiponectin. Metformin 97-106 C-reactive protein Homo sapiens 181-199 23981104-6 2014 RESULTS: Metformin significantly reduced levels of vWF, sVCAM-1, t-PA, PAI-1, CRP and sICAM-1, which, except for CRP, remained significant after adjustment for baseline differences in age, sex, smoking and severity of previous cardiovascular (CV) disease. Metformin 9-18 C-reactive protein Homo sapiens 78-81 25555182-7 2014 CRP was decreased with metformin (P<0.001), but was increased with OCPs (P<0.001). Metformin 23-32 C-reactive protein Homo sapiens 0-3 25555182-9 2014 OCPs and metformin appear to have differential effects on atherogenic molecules in lean PCOS patients, but metformin was superior in reducing serum AGEs and CRP. Metformin 107-116 C-reactive protein Homo sapiens 157-160 24622715-15 2014 Patients taking metformin had lower HbA1c, insulin, HOMA-IR, and tissue plasminogen activator compared with those taking placebo, but there were no significant differences for total cholesterol, HDL-cholesterol, non-HDL-cholesterol, triglycerides, high sensitivity C-reactive protein, or fasting glucose. Metformin 16-25 C-reactive protein Homo sapiens 265-283 23981104-6 2014 RESULTS: Metformin significantly reduced levels of vWF, sVCAM-1, t-PA, PAI-1, CRP and sICAM-1, which, except for CRP, remained significant after adjustment for baseline differences in age, sex, smoking and severity of previous cardiovascular (CV) disease. Metformin 9-18 C-reactive protein Homo sapiens 113-116 23988170-16 2013 The most important predictors for duration of metformin treatment in PCOS women were testosterone, progesterone, FSH, CRP and presence of anovulation. Metformin 46-55 C-reactive protein Homo sapiens 118-121 23279603-5 2013 Serum concentration of hs-CRP significantly decreased in both the Metformin (5.29 +- 2.50 vs 3.81 +- 1.99, P = 0.008) and diet groups (6.08 +- 2.14 vs 4.27 +- 1.60, P = 0.004). Metformin 66-75 C-reactive protein Homo sapiens 26-29 23279603-0 2013 Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. Metformin 10-19 C-reactive protein Homo sapiens 60-78 23279603-9 2013 CONCLUSIONS: Although weight reduction has equal efficacy with Metformin in decreasing serum hs-CRP levels, it was significantly more effective in improving insulin resistance in obese and overweight PCOS women. Metformin 63-72 C-reactive protein Homo sapiens 96-99 23279603-1 2013 AIM: The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS). Metformin 69-78 C-reactive protein Homo sapiens 115-133 23279603-1 2013 AIM: The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS). Metformin 69-78 C-reactive protein Homo sapiens 135-138 23674518-4 2013 We also studied the effect of metformin therapy on the CRP-leptin correlation in patients with newly diagnosed diabetes. Metformin 30-39 C-reactive protein Homo sapiens 55-58 23674518-11 2013 This is the first report demonstrating the restorative role of metformin on the leptin-CRP correlation in patients with newly diagnosed diabetes. Metformin 63-72 C-reactive protein Homo sapiens 87-90 23378779-13 2013 Similarly, a fall in C-reactive protein and adenosine deaminase levels was greater in patients taking metformin with garlic than in patients taking only metformin. Metformin 102-111 C-reactive protein Homo sapiens 21-39 23359066-3 2013 METHODS AND RESULTS: The primary objective of this study was to evaluate the effect on C-reactive protein (CRP) after a 16-week treatment period with either pioglitazone or metformin. Metformin 173-182 C-reactive protein Homo sapiens 87-105 23359066-3 2013 METHODS AND RESULTS: The primary objective of this study was to evaluate the effect on C-reactive protein (CRP) after a 16-week treatment period with either pioglitazone or metformin. Metformin 173-182 C-reactive protein Homo sapiens 107-110 23378779-13 2013 Similarly, a fall in C-reactive protein and adenosine deaminase levels was greater in patients taking metformin with garlic than in patients taking only metformin. Metformin 153-162 C-reactive protein Homo sapiens 21-39 23107042-5 2012 Metformin, but not placebo, administered to simvastatin-treated IFG subjects reduced plasma levels of C-reactive protein, soluble intercellular adhesion molecule-1, as well as lymphocyte release of interleukin-2, interferon-gamma and tumor necrosis factor-alpha, which was accompanied by the improvement in insulin sensitivity and a reduction in free fatty acid levels. Metformin 0-9 C-reactive protein Homo sapiens 102-120 22841520-5 2013 RESULTS: Compared to placebo, metformin reduced monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, monocyte chemoattractant protein-1 and interleukin-8, as well as decreased plasma C-reactive protein levels, which were accompanied by an improvement in insulin sensitivity. Metformin 30-39 C-reactive protein Homo sapiens 213-231 24399727-6 2013 RESULTS: Metformin treatment reduced plasma C-reactive protein levels and monocyte release of tumor necrosis factor-alpha and interleukin-6, as well as tended to reduce monocyte release of interleukin-1beta and monocyte chemoattractant protein-1, which was accompanied by an improvement in insulin sensitivity. Metformin 9-18 C-reactive protein Homo sapiens 44-62 23677182-0 2012 [Effect of metformin on the expression of tumor necrosis factor-alpha, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients]. Metformin 11-20 C-reactive protein Homo sapiens 99-117 22525206-11 2012 CONCLUSIONS: Metformin has no effect on blood pressure and blood glucose levels, but it does reduce total cholesterol, abdominal obesity and C-reactive protein levels in obese hypertensive patients without diabetes. Metformin 13-22 C-reactive protein Homo sapiens 141-159 22375259-0 2012 Comparative Effects of Glibenclamide and Metformin on C-Reactive Protein and Oxidant/Antioxidant Status in Patients with Type II Diabetes Mellitus. Metformin 41-50 C-reactive protein Homo sapiens 54-72 22713099-1 2012 BACKGROUND: We are hereby investigating for the first time the effect of the association ethinylestradiol30mug-drospirenone 3mg (DRP/EE30mug) plus metformin and weight loss on endothelial status and C-reactive protein (hsCRP) levels in polycystic ovary syndrome (PCOS). Metformin 147-156 C-reactive protein Homo sapiens 199-217 22375259-1 2012 OBJECTIVES: This study aimed to compare the effects of metformin and glibenclamide on high sensitivity serum C-reactive protein (hs-CRP) and oxidative stress, represented by serum malondialdehyde (MDA) and total antioxidant status (TAS) in newly-diagnosed patients with Type 2 diabetes mellitus (DM) at baseline and after 2 months of therapy in comparison to controls. Metformin 55-64 C-reactive protein Homo sapiens 109-127 21146883-7 2011 Significant restoration of C reactive protein (p<0.05) was noticed after metformin therapy. Metformin 76-85 C-reactive protein Homo sapiens 27-45 21865358-9 2011 Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. Metformin 21-30 C-reactive protein Homo sapiens 124-142 19937362-9 2010 There was also significant reductions in serum C reactive protein levels in both sibutramine (P = 0.045, P = 0.02) and sibutramine plus metformin groups (P = 0.007, P = 0.001) after 3 and 12 months, respectively. Metformin 136-145 C-reactive protein Homo sapiens 47-65 19488607-1 2009 OBJECTIVE: To study if metformin, when administered to first-degree relatives of type 2 diabetes mellitus subjects who have metabolic syndrome and normal glucose tolerance, could improve the cardiovascular risk profile and reduce the levels of both C-reactive protein and fibrinogen. Metformin 23-32 C-reactive protein Homo sapiens 249-267 19808911-3 2010 RESEARCH DESIGN AND METHODS: In A Diabetes Outcome Progression Trial (ADOPT), we examined the long-term effects of rosiglitazone, glyburide, and metformin on CRP and the relationship among CRP, weight, and glycemic variables in 904 subjects over 4 years. Metformin 145-154 C-reactive protein Homo sapiens 158-161 19808911-5 2010 CRP reduction was greater in the rosiglitazone group by -47.6% relative to glyburide and by -30.5% relative to metformin at 48 months. Metformin 111-120 C-reactive protein Homo sapiens 0-3 19808911-7 2010 The change in CRP from baseline to 12 months was correlated positively with change in BMI in glyburide (r = 0.18) and metformin (r = 0.20) groups but not in the rosiglitazone (r = -0.05, NS) group. Metformin 118-127 C-reactive protein Homo sapiens 14-17 19808911-10 2010 CRP in the glyburide and metformin groups was positively associated with changes in weight, but this was not the case with rosiglitazone. Metformin 25-34 C-reactive protein Homo sapiens 0-3 18346173-17 2008 In addition, in patients given metformin, CRP levels decreased. Metformin 31-40 C-reactive protein Homo sapiens 42-45 19188739-4 2009 After 6 weeks of metformin therapy (n = 37) there was a significant reduction in BMI (p < 0.001), waist (p < 0.001) and CRP (p < 0.01), while at 6 months there was not only a significant reduction in BMI and waist but also in HOMA-R (p = 0.01) and IL-6 levels (p < 0.01) with no further reduction of CRP. Metformin 17-26 C-reactive protein Homo sapiens 126-129 19188739-4 2009 After 6 weeks of metformin therapy (n = 37) there was a significant reduction in BMI (p < 0.001), waist (p < 0.001) and CRP (p < 0.01), while at 6 months there was not only a significant reduction in BMI and waist but also in HOMA-R (p = 0.01) and IL-6 levels (p < 0.01) with no further reduction of CRP. Metformin 17-26 C-reactive protein Homo sapiens 312-315 19188739-6 2009 While short-term metformin therapy facilitates weight loss with a concomitant reduction in CRP, long-term therapy results in a reduction of IL-6 and insulin resistance. Metformin 17-26 C-reactive protein Homo sapiens 91-94 19188739-7 2009 Metformin-associated reduction of CRP levels prior to any significant changes in insulin resistance or IL-6 perhaps involves different mechanisms of action. Metformin 0-9 C-reactive protein Homo sapiens 34-37 17548076-11 2008 After hCG injection, CRP increased in both the metformin and the placebo groups with no significant difference between the groups. Metformin 47-56 C-reactive protein Homo sapiens 21-24 17489777-13 2007 Metformin therapy in PCOS women reduces CRP level, hyperinsulinaemia and cardiovascular risk. Metformin 0-9 C-reactive protein Homo sapiens 40-43 17307426-7 2007 High-sensitivity C-reactive protein levels decreased by an average of 68% in the rosiglitazone group (5.99 +/- 0.88 to 1.91 +/- 0.28 mg/L, P < .001), compared with a nonsignificant 4% reduction in hsCRP with metformin (5.69 +/- 0.83 to 5.46 +/- 0.92 mg/L; P = nonsignificant). Metformin 211-220 C-reactive protein Homo sapiens 17-35 17489777-8 2007 Mean serum C-RP levels significantly decreased after metformin treatment ((6,37+/-1,72 vs. 1,67+/-0,73 mg/l; p<0,05). Metformin 53-62 C-reactive protein Homo sapiens 11-15 16472047-6 2006 Metformin is known to reduce the risk of developing diabetes, and more recent evidence suggests it also lowers C-reactive protein, in part because of its modest weight-reducing effect. Metformin 0-9 C-reactive protein Homo sapiens 111-129 16957566-6 2006 Addition of rosiglitazone to metformin also reduced levels of plasminogen activator inhibitor-1 antigen and activity, C-reactive protein, von Willebrand factor and fibrinogen compared with addition of glyburide. Metformin 29-38 C-reactive protein Homo sapiens 118-159 16108864-0 2005 Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus. Metformin 0-9 C-reactive protein Homo sapiens 18-36 16108864-1 2005 AIMS: To determine the influence of metformin treatment on plasma C-reactive protein (CRP) and complement factor C3. Metformin 36-45 C-reactive protein Homo sapiens 66-84 16108864-1 2005 AIMS: To determine the influence of metformin treatment on plasma C-reactive protein (CRP) and complement factor C3. Metformin 36-45 C-reactive protein Homo sapiens 86-89 16108864-8 2005 The difference in ratios of CRP levels at each visit to baseline between placebo- (n = 16) and metformin-treated (n = 26) subjects was significantly different at the 12-week (P = 0.002) and 24-week (P = 0.03) visits. Metformin 95-104 C-reactive protein Homo sapiens 28-31 16108864-13 2005 CONCLUSION: Metformin may have a specific interaction with mechanisms involved in CRP synthesis or secretion, not directly related to improved insulin sensitivity and dampening of chronic inflammation. Metformin 12-21 C-reactive protein Homo sapiens 82-85 15855347-5 2005 Metformin reduced CRP in women compared with the placebo group. Metformin 0-9 C-reactive protein Homo sapiens 18-21 15855347-7 2005 In women, the changes in CRP from baseline to follow-up were -29% in the lifestyle group, -14% in the metformin group, and 0% in the placebo group. Metformin 102-111 C-reactive protein Homo sapiens 25-28 15901207-7 2005 Metformin improves dyslipidemia and altered hemostasis and decreases plasma C-reactive protein levels with little or no effect on blood pressure. Metformin 0-9 C-reactive protein Homo sapiens 76-94 12738395-13 2003 CRP was positively associated with body mass index (BMI), serum triglycerides, and sulfonylurea therapy and negatively associated with metformin therapy. Metformin 135-144 C-reactive protein Homo sapiens 0-3 15236798-3 2004 Strategies for decreasing elevated CRP include administration of statins, thiazolidinediones, and metformin; moderate alcohol consumption and appropriate weight loss are also helpful in this regard. Metformin 98-107 C-reactive protein Homo sapiens 35-38 15236798-6 2004 Thus, it is proposed that metformin--or AMPK---inhibits hepatic CRP production by boosting hepatic nitric oxide synthesis, which in turn impedes Stat3 activation and CRP transcription. Metformin 26-35 C-reactive protein Homo sapiens 64-67 15236798-6 2004 Thus, it is proposed that metformin--or AMPK---inhibits hepatic CRP production by boosting hepatic nitric oxide synthesis, which in turn impedes Stat3 activation and CRP transcription. Metformin 26-35 C-reactive protein Homo sapiens 166-169 14557435-0 2003 Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. Metformin 0-9 C-reactive protein Homo sapiens 24-42 14557435-2 2003 Because the insulin sensitizer metformin has been shown to improve metabolic disturbances in PCOS, it was of particular interest to examine serum CRP levels during metformin therapy. Metformin 164-173 C-reactive protein Homo sapiens 146-149 14557435-5 2003 During metformin treatment, serum CRP levels decreased significantly from 3.08 +/- 0.7 mg/liter to 1.52 +/- 0.26 mg/liter at 6 months in the whole study population (P = 0.006) and especially in obese subjects. Metformin 7-16 C-reactive protein Homo sapiens 34-37 14557435-8 2003 The decrease of serum CRP levels during metformin therapy is in accordance with the known beneficial metabolic effects of this drug and suggests that CRP or other inflammation parameters could be used as markers of treatment efficiency in women with PCOS. Metformin 40-49 C-reactive protein Homo sapiens 22-25 14557435-8 2003 The decrease of serum CRP levels during metformin therapy is in accordance with the known beneficial metabolic effects of this drug and suggests that CRP or other inflammation parameters could be used as markers of treatment efficiency in women with PCOS. Metformin 40-49 C-reactive protein Homo sapiens 150-153 14502100-5 2003 Metformin has a weight neutral/weight lowering effect and reduces hypertriglyceridaemia, elevated levels of PAI-1, factor VII and C-reactive protein. Metformin 0-9 C-reactive protein Homo sapiens 130-148 33798839-6 2021 Meta-analysis of 2 studies including 323 pregnant women showed significantly reduced CRP levels following treatment with metformin compared to placebo [mean difference = -1.72, 95% CI (-2.97; -0.48); p = 0.007]. Metformin 121-130 C-reactive protein Homo sapiens 85-88 12721499-0 2003 Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Metformin 10-19 C-reactive protein Homo sapiens 40-58 12721499-1 2003 The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome. Metformin 86-95 C-reactive protein Homo sapiens 183-201 12721499-1 2003 The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome. Metformin 86-95 C-reactive protein Homo sapiens 203-206 12721499-8 2003 CRP level was significantly lower in patients using metformin for blood glucose control compared with those using glibenclamide, 5.56 and 8.3 mg/L, respectively (p = 0.01). Metformin 52-61 C-reactive protein Homo sapiens 0-3 12721499-11 2003 The data showed that metformin decreases the level of circulating CRP, a marker of inflammation, more than glibenclamide. Metformin 21-30 C-reactive protein Homo sapiens 66-69 35351535-8 2022 After 24-weeks, metformin therapy for the intervention group resulted in a significant decrease of HbA1c, CRP, UACR, total cholesterol and CIMT while Nrg-4 levels were increased compared with baseline levels (p<0.001) and with placebo group(p<0.001). Metformin 16-25 C-reactive protein Homo sapiens 106-109 34717078-8 2021 Additionally, the meta-analysis revealed that circulating tumor necrosis factor-alpha(TNF-alpha) and C-reactive protein (CRP) concentrations were significantly decreased after metformin treatment, with corresponding SMDs of 1.01 (95% CI: 0.74-1.28, P<0.00001) and 0.48(95% CI: 0.35-0.60, P<0.00001). Metformin 176-185 C-reactive protein Homo sapiens 101-119 34717078-8 2021 Additionally, the meta-analysis revealed that circulating tumor necrosis factor-alpha(TNF-alpha) and C-reactive protein (CRP) concentrations were significantly decreased after metformin treatment, with corresponding SMDs of 1.01 (95% CI: 0.74-1.28, P<0.00001) and 0.48(95% CI: 0.35-0.60, P<0.00001). Metformin 176-185 C-reactive protein Homo sapiens 121-124 35620570-3 2022 Results: The empagliflozin-metformin combination increased levels of the antioxidants (TAS, SOD, and GPx up to 1.1-fold; P < 0.01), decreased the levels of prooxidants (AOPP and isoprostanes up to 1.2-fold, P < 0.01; AGE up to 1.5-fold, P < 0.01), and decreased inflammatory parameters (up to 1.5-fold, CRP P < 0.01; IL-6 P < 0.001). Metformin 27-36 C-reactive protein Homo sapiens 303-306 34630103-8 2021 Metformin significantly decreased CRP levels and DAS-28-CRP after 6 months compared to the control group (p-value <0.001). Metformin 0-9 C-reactive protein Homo sapiens 34-37 34630103-8 2021 Metformin significantly decreased CRP levels and DAS-28-CRP after 6 months compared to the control group (p-value <0.001). Metformin 0-9 C-reactive protein Homo sapiens 56-59 35268272-9 2022 PWVcf and CRP were negatively correlated (r = 0.571) in the T2DM subjects treated with metformin in the AAA group. Metformin 87-96 C-reactive protein Homo sapiens 10-13 35268272-13 2022 The negative correlation between CRP and PWVcf in males with T2DM treated with metformin may indicate that metformin influences the arterial wall to decrease stiffness in subjects with AAA. Metformin 79-88 C-reactive protein Homo sapiens 33-36 35268272-13 2022 The negative correlation between CRP and PWVcf in males with T2DM treated with metformin may indicate that metformin influences the arterial wall to decrease stiffness in subjects with AAA. Metformin 107-116 C-reactive protein Homo sapiens 33-36 34676406-8 2022 Furthermore, in diabetic patients, Metformin treatment was associated with lower high-sensitivity C-reactive protein levels. Metformin 35-44 C-reactive protein Homo sapiens 98-116